2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/14/17Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., a Delaware corporation (the "Company"), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA™) constructs, today reported its financial results for the third quarter ended September 30, 2017. "The third quarter was a transformational period for the Company. We continued to advance two SNA drug candidates toward their Phase 1 clinical trials and be... 
Printer Friendly Version
11/06/17Exicure, Inc. Closes Additional $11.2 Million in Private Financing to Advance its Gene Regulatory and Immunotherapeutic Programs
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA™) constructs, today announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures. In the initial closing of this private placement announced in September, Exicure ... 
Printer Friendly Version
09/27/17Exicure, Inc. Successfully Completes Reverse Merger and Closes $20 Million Private Placement
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in developing three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced the closing of a $20 million private placement financing and the completion of a reverse merger transaction, with Max-1 Acquisition Corporation. Following the reverse merger transaction, Max-1 changed its name to Exicure, Inc. (the "Company"), and will continue the hi... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet